ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High
Net Cost Of Alzheimer’s Drug May Still Be Within Range
The drug pricing watchdog said in its revised report that Alzheimer’s therapy Leqembi (lecanemab) meets cost-effectiveness thresholds at $8,900-$21,500, below Eisai/Biogen’s $26,500 list price.
